help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PRIETO, A.
Right arrow Articles by ALVAREZ-MON, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PRIETO, A.
Right arrow Articles by ALVAREZ-MON, M.

Am. J. Respir. Crit. Care Med., Volume 163, Number 7, June 2001, 1578-1583

Defective Natural Killer and Phagocytic Activities in Chronic Obstructive Pulmonary Disease Are Restored by Glycophosphopeptical (Inmunoferón)

ALFREDO PRIETO, EDUARDO REYES, ERICA D. BERNSTEIN, BELÉN MARTINEZ, JORGE MONSERRAT, JOSE LUIZ IZQUIERDO, LUIS CALLOL, PILAR de LUCAS, RUDOLFO ALVAREZ-SALA, JOSÉ LUIS ALVAREZ-SALA, VICENTE G. VILLARRUBIA, and MELCHOR ALVAREZ-MON

Department of Medicine CSIC Associated Unit, University of Alcalá, Alcalá de Henares, Madrid; Department of Medicine, Hospital General Universitario, Guadalajara; Department of Medicine, Hospital del Aire, Madrid; Department of Medicine, Hospital Universitario Gregorio Marañon, Madrid; Department of Medicine, Hospital Universitario La Paz, Madrid; Pulmonary Service, San Carlos University Hospital, Madrid; Department of Immunology, I.F. Cantabria, Madrid; and Medicine and Immune System Diseases and Oncology Service, University Hospital "Príncipe de Asturias," Alcalá de Henares, Madrid, Spain

We have investigated both modifications in natural (innate) immunity caused by chronic obstructive pulmonary disease (COPD) and the effects of a glycophosphopeptical immunomodulator (Inmunoferón) treatment on COPD-associated immunoalterations. In a double-blinded clinical trial, 60 patients with COPD received glycophosphopeptical or placebo during 90 consecutive days at oral doses of 3 g/d. Fifty-six sex- and age-matched healthy control subjects were included as a reference group for immunologic parameters. Peripheral blood natural killer (PBNK) cell cytotoxic activity and phagocytic activity of peripheral monocytes/macrophages (Mo/Ma) and polymorphonuclear (PMN) cells were assessed at baseline and then again at the end of treatments. We found both PBNK activity and phagocytic activity to be significantly decreased in patients with COPD compared with levels in healthy volunteers. The treatment with glycophosphopeptical provoked significant stimulatory effects on PBNK cytotoxic activity. This stimulation was not mediated by an increase in CD3-CD56+ NK cells. Further, glycophosphopeptical significantly increased the percentage of monocytes and PMNs that phagocytize Escherichia coli in vitro, as well as increased phagocytic indices. We conclude that peripheral blood cells of patients with COPD show clear defects in natural immunity that are partially rescued by glycophosphopeptical.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
C. Crim, P. M. A. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, L. R. Willits, J. C. Yates, and J. Vestbo
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Eur. Respir. J., September 1, 2009; 34(3): 641 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. J. Barnes and B. R. Celli
Systemic manifestations and comorbidities of COPD
Eur. Respir. J., May 1, 2009; 33(5): 1165 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
M. Miravitlles
Review: Do we need new antibiotics for treating exacerbations of COPD?
Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 61 - 76.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
N. Minematsu and S. D. Shapiro
To Live and Die in the LA (Lung Airway): Mode of Neutrophil Death and Progression of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 129 - 130.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Serrano-Gomez, R. T. Martinez-Nunez, E. Sierra-Filardi, N. Izquierdo, M. Colmenares, J. Pla, L. Rivas, J. Martinez-Picado, J. Jimenez-Barbero, J. L. Alonso-Lebrero, et al.
AM3 Modulates Dendritic Cell Pathogen Recognition Capabilities by Targeting DC-SIGN
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2313 - 2323.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. M. Henson, G. P. Cosgrove, and R. W. Vandivier
State of the Art. Apoptosis and Cell Homeostasis in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, August 1, 2006; 3(6): 512 - 516.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
K. Rydell-Tormanen, L. Uller, and J. S. Erjefalt
Direct evidence of secondary necrosis of neutrophils during intense lung inflammation
Eur. Respir. J., August 1, 2006; 28(2): 268 - 274.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Reyes, A. Prieto, A. de la Hera, P. de Lucas, R. Alvarez-Sala, J. L. Alvarez-Sala, and M. Alvarez-Mon
Treatment With AM3 Restores Defective T-Cell Function in COPD Patients
Chest, March 1, 2006; 129(3): 527 - 535.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Alvarez-Mon, M. Miravitlles, J. Morera, L. Callol, and J. L. Alvarez-Sala
Treatment With the Immunomodulator AM3 Improves the Health-Related Quality of Life of Patients With COPD
Chest, April 1, 2005; 127(4): 1212 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes
Mediators of Chronic Obstructive Pulmonary Disease
Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. Gamble, D. C. Grootendorst, C. E. Brightling, S. Troy, Y. Qiu, J. Zhu, D. Parker, D. Matin, S. Majumdar, A. M. Vignola, et al.
Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 976 - 982.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.J. Barnes, S.D. Shapiro, and R.A. Pauwels
Chronic obstructive pulmonary disease: molecular and cellularmechanisms
Eur. Respir. J., October 1, 2003; 22(4): 672 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Inoue, H. Nakamura, K. Otake, H. Saito, K. Terashita, J. Sato, H. Takeda, and H. Tomoike
Impaired Pulmonary Inflammatory Responses Are a Prominent Feature of Streptococcal Pneumonia in Mice with Experimental Emphysema
Am. J. Respir. Crit. Care Med., March 1, 2003; 167(5): 764 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Miravitlles
Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?
Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  2nd Annual Dinner